Phase 1b/2 trial of ribociclib plus binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D).

被引：23

作者：

Schuler, Martin H.

Ascierto, Paolo A.

de Vos, Filip Yves Francine Leon

Postow, Michael Andrew

Van Herpen, Carla M. L.

Carlin, Matteo S.

Sosman, Jeffrey A.

Berking, Carola

Long, Georgina V.

Weise, Amy

Gutzmer, Ralf

Kaatz, Martin

McArthur, Grant A.

Schwartz, Gary

Daud, Adil

Maharry, Kati

Yerramilli-Rao, Padmaja

Zimmer, Lisa

Bozon, Viviana

Amaria, Rodabe Navroze

机构：

[1] Univ Hosp, West German Canc Ctr, Essen, Germany

[2] Ist Nazl Tumori Fdn G Pascale IRCCS, Naples, Italy

[3] Univ Med Ctr Utrecht, Canc Ctr, Dept Med Oncol, Utrecht, Netherlands

[4] Weill Cornell Med Coll, New York, NY USA

[5] Mem Sloan Kettering Canc Ctr, New York, NY USA

[6] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands

[7] Westmead & Blacktown Hosp, Sydney, NSW, Australia

[8] Melanoma Inst Australia, Sydney, NSW, Australia

[9] Northwestern Univ, Robert H Lurie Canc Ctr, Chicago, IL USA

[10] Univ Hosp Munich LMU, Dept Dermatol & Allergy, Munich, Germany

[11] Univ Sydney, Melanoma Inst Australia, Royal North Shore & Mater Hosp, Sydney, NSW, Australia

[12] Karmanos Canc Inst, Detroit, MI USA

[13] Hannover Med Sch, Skin Canc Ctr Hannover, Hannover, Germany

[14] SRH Wald Klinikum Gera GmbH, Gera, Germany

[15] Peter MacCallum Canc Ctr, Melbourne, Australia

[16] Columbia Coll Phys & Surg, New York, NY USA

[17] UCSF Helen Diller Family Comprehens Canc Ctr, Melanoma Clin Res, San Francisco, CA USA

[18] Array BioPharma Inc, Boulder, CO USA

[19] Novartis Inst BioMed Res, Cambrdige, MA USA

[20] Univ Texas MD Anderson Canc Ctr, Melanoma Med Oncol, Houston, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.9519

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9519

引用

页数：5

共 50 条

[31] A phase (Ph) 1b/2 study of ribociclib (R) in combination with docetaxel (D) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).
de Kouchkovsky, Ivan
Rao, Arpit
Carneiro, Benedito A.
Zhang, Li
Lewis, Catriona
Phone, Audrey
Small, Eric Jay
Friedlander, Terence W.
Fong, Lawrence
Paris, Pamela
Ryan, Charles J.
Szmulewitz, Russell Zelig
Aggarwal, Rahul Raj
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[32] A Phase 1b/2 Open-label Clinical Trial to Evaluate the Safety and Efficacy of AU-011 for the Treatment of Choroidal Melanoma
Mruthyunjaya, Prithvi
Schefler, Amy C.
Kim, Ivana K.
Bergstrom, Christopher
Demirci, Hakan
Tsai, Tony
Bhavsar, Abdhish R.
Capone, Antonio
Marr, Brian
McCannel, Tara A.
Javid, Cameron
Hovland, Peter G.
Seider, Michael I.
Rich, Cadmus
Shields, Carol L.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
[33] Identification of the recommended phase II dose (RP2D) of the c-Met Inhibitor tepotinib (MSC2156119J) in Japanese patients (pts) with solid tumors: A phase I trial
Yamazaki, K.
Tsushima, T.
Shitara, K.
Sarholz, B.
Fujita, M.
Doi, T.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S75 - S76
[34] PHASE 1B TRIAL OF MONALIZUMAB (NKG2A INHIBITOR) PLUS DURVALUMAB: SAFETY AND EFFICACY IN PATIENTS WITH METASTATIC OVARIAN, CERVICAL, AND MICROSATELLITE-STABLE ENDOMETRIAL CANCERS
Banerjee, Susana
Oaknin, Ana
Sanchez-Simon, Inmaculada
Salgado, Alfonso Cortes
Patel, Sandip Pravin
Oza, Amit
Das, Mayukh
Kourtesis, Panagiotis
Ascierto, Maria Libera
Diamond, Jennifer R.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A86 - A87
[35] A phase 1b lead-in to a randomized phase 2 trial of lurbinectedin plus doxorubicin in leiomyosarcoma (LMS)
Cote, Gregory Michael
Choy, Edwin
Thornton, Katherine Anne
Mazzola, Emanuele
Bouberhan, Sara
Merriam, Priscilla
Wagner, Andrew J.
Morgan, Jeffrey A.
Haddox, Candace L.
Oza, Jay
Demetri, George D.
George, Suzanne
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[36] Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma
Dummer, R.
Ascierto, P. A.
Gogas, H.
Arance, A.
Mandala, M.
Liszkay, G.
Garbe, C.
Schadendorf, D.
Krajsova, I.
Gutzmer, R.
Sileni, V. Chiarion
Dutriaux, C.
de Groot, J. W. B.
Yamazaki, N.
Loquai, C.
de Parseval, L. A.
Pickard, M.
Sandor, V.
Robert, C.
Flaherty, K. T.
ANNALS OF ONCOLOGY, 2017, 28
[37] A phase 1 study to evaluate the safety and tolerability of bevacizumab-niraparib combination therapy and determine the recommended phase 2 dose (RP2D) in women with platinum-sensitive epithelial ovarian cancer (ENGOT-OV24/AVANOVA1)
Mirza, M. R.
Wang, J.
Mau-Sorensen, M.
Birrer, M. J.
Wang, X.
Jorgensen, M.
Zhang, Z-Y.
Roed, H.
Malander, S.
Nielsen, F.
Bjorge, L.
Lassen, U.
Boufercha, L.
Brosen, K.
Kansra, V.
Maenpaa, J.
ANNALS OF ONCOLOGY, 2017, 28
[38] A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma
Lee, C-H.
Makker, V.
Rasco, D.
Taylor, M.
Dutcus, C.
Shumaker, R.
Schmidt, E. V.
Stepan, D.
Li, D.
Motzer, R. J.
ANNALS OF ONCOLOGY, 2017, 28
[39] A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma
Mao, Lili
Guo, Jun
Zhu, Lingjun
Jiang, Yu
Yan, Wangjun
Zhang, Jian
Hui, Ai-Min
Yang, Yuchen
Diao, Lei
Tan, Yan
Zhao, Han
Jiang, Yiqian
Wu, Zhuli
Si, Lu
EUROPEAN JOURNAL OF CANCER, 2022, 175 : 125 - 135
[40] POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis
Menzies, Alexander M.
Long, Georgina, V
Kohn, Amiee
Tawbi, Hussein
Weber, Jeffrey
Flaherty, Keith
McArthur, Grant A.
Ascierto, Paolo A.
Pfluger, Yanina
Lewis, Karl
Tsai, Katy K.
Hamid, Omid
Prenen, Hans
Fein, Luis
Wang, Erjian
Guenzel, Carolin
Zhang, Fan
Kleha, Joseph F.
di Pietro, Alessandra
Davies, Michael A.
NEURO-ONCOLOGY ADVANCES, 2024, 6 (01)

← 1 2 3 4 5 →